Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...

ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...

Promising ovarian cancer research by Melanie Rutkowski, PhD, at the University of Virginia Comprehensive Cancer Center has ...

University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for ...

Therapeutics, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETX-19477, the company’s internally ...

Ovarian cancer is one of the most common forms of cancer, a type that usually remains undiagnosed for a while in many ...

The American College of Medical Genetics and Genomics (ACMG) has published a new clinical practice resource, "Management of Individuals with Heterozygous Germline Pathogenic Variants in RAD51C, RAD51D ...

The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...